Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
Results Of The Global Phase 3 Trial, Now Published In Clinical Infectious Diseases, Show For The Primary Endpoint, LIVTENCITY Was Statistically Superior To Conventional Therapies...